Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.5217/ir.2013.11.4.256 http://hdl.handle.net/11449/136813 |
Resumo: | In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD. |
id |
UNSP_dba450949f2d6f541f619d1d9a64783b |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/136813 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?Tumor necrosis factor alphaCrohn’s diseaseRecurrenceIn most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD.Pontifícia Universidade Católica do Paraná (PUC-PR), Departamento de Cirurgia, Curitiba, PR, BrasilUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, BrasilUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, BrasilPontifícia Universidade Católica do Paraná (PUC-PR)Universidade Estadual Paulista (Unesp)Kotze, Paulo GustavoHossne, Rogério Saad [UNESP]2016-04-01T18:42:42Z2016-04-01T18:42:42Z2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article256-260application/pdfhttp://dx.doi.org/10.5217/ir.2013.11.4.256Intestinal Research, v. 11, n. 4, p. 256-260, 2013.1598-9100http://hdl.handle.net/11449/13681310.5217/ir.2013.11.4.256ISSN1598-9100-2013-11-04-256-260.pdf952634515659047795263451565904779526345156590477Currículo Lattesreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengIntestinal Research1,074info:eu-repo/semantics/openAccess2024-08-14T14:19:17Zoai:repositorio.unesp.br:11449/136813Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T14:19:17Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
title |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
spellingShingle |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? Kotze, Paulo Gustavo Tumor necrosis factor alpha Crohn’s disease Recurrence |
title_short |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
title_full |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
title_fullStr |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
title_full_unstemmed |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
title_sort |
Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? |
author |
Kotze, Paulo Gustavo |
author_facet |
Kotze, Paulo Gustavo Hossne, Rogério Saad [UNESP] |
author_role |
author |
author2 |
Hossne, Rogério Saad [UNESP] |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Pontifícia Universidade Católica do Paraná (PUC-PR) Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Kotze, Paulo Gustavo Hossne, Rogério Saad [UNESP] |
dc.subject.por.fl_str_mv |
Tumor necrosis factor alpha Crohn’s disease Recurrence |
topic |
Tumor necrosis factor alpha Crohn’s disease Recurrence |
description |
In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 2016-04-01T18:42:42Z 2016-04-01T18:42:42Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.5217/ir.2013.11.4.256 Intestinal Research, v. 11, n. 4, p. 256-260, 2013. 1598-9100 http://hdl.handle.net/11449/136813 10.5217/ir.2013.11.4.256 ISSN1598-9100-2013-11-04-256-260.pdf 9526345156590477 9526345156590477 9526345156590477 |
url |
http://dx.doi.org/10.5217/ir.2013.11.4.256 http://hdl.handle.net/11449/136813 |
identifier_str_mv |
Intestinal Research, v. 11, n. 4, p. 256-260, 2013. 1598-9100 10.5217/ir.2013.11.4.256 ISSN1598-9100-2013-11-04-256-260.pdf 9526345156590477 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Intestinal Research 1,074 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
256-260 application/pdf |
dc.source.none.fl_str_mv |
Currículo Lattes reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128168788230144 |